Immunosuppressive agents in lupus nephritis: a critical analysis.
D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D005921:Glomerulonephritis / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007668:Kidney / Q000473:pathology; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008466:Mechlorethamine / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis
D007166:Immunosuppressive Agents; D008466:Mechlorethamine; D003520:Cyclophosphamide; D001379:Azathioprine; D011241:Prednisone